#United States #Huntsville #Leadership #Gannet BioChem #Dr. Harry Rathore

Gannet BioChem Welcomes Dr. Harry Rathore to Its Board of Directors

Gannet BioChem, a prominent player in the specialty chemicals sector, has made a significant move by appointing Dr. Harry Rathore to its Board of Directors as part of its strategic growth plan. This announcement comes on the heels of Gannet's acquisition by Ampersand Capital Partners, a private equity firm known for its investments in life sciences and healthcare.

Dr. Rathore's extensive experience spans more than 35 years, covering various sectors including specialty chemicals, pharmaceuticals, and Contract Development and Manufacturing Organizations (CDMOs). His diverse leadership roles have made him a valued asset in the industry. Currently, he serves as a Board Member and Strategic Advisor for Ascensus Specialties and VanDeMark, Inc. Additionally, Dr. Rathore has previously held executive positions including President and CEO of Callery Inc., and has been a key figure at Lonza AG, Alcami, and Borregaard Synthesis. His entrepreneurial spirit is reflected in his establishment of PolyOrganix, Inc., a firm dedicated to specialty pharmaceuticals and fine chemicals. Dr. Rathore's academic credentials include a Ph.D. in Medicinal Chemistry from Oregon State University, complemented by both a Master’s and Bachelor’s in Pharmaceutical Sciences from Banaras Hindu University.

Nick Shackley, CEO of Gannet BioChem, expressed enthusiasm about Dr. Rathore's appointment, stating, "With a strong background building and advising businesses in the specialty chemical and pharmaceutical industries, Harry will provide valuable insight and guidance to enable Gannet BioChem's growth and innovation." Shackley outlined that they are eager to collaborate with Dr. Rathore as the company executes its growth initiatives that support global therapeutics.

In his own words, Dr. Rathore remarked on the significance of his new role, stating, "I'm honored to join the Board of Directors at Gannet BioChem during such a pivotal time in the company's growth. With a proven track record spanning 30 years, Gannet's specialized capabilities in PEG reagents, bioconjugation, and GMP manufacturing are essential to advancing the next generation of biopharmaceuticals." His commitment to enhancing the capabilities of Gannet BioChem is evident, reflecting a shared vision for innovation and excellence in the biotech field.

About Gannet BioChem

With over three decades of expertise in the industry, Gannet BioChem stands out as a leading specialty CDMO specializing in the development, scaling, and manufacturing of polyethylene glycol (PEG) reagents. These reagents are crucial components in advanced biopharmaceutical and therapeutic products. The company operates from a state-of-the-art facility located in Huntsville, Alabama, which spans 124,000 square feet and is FDA-inspected. This modern setup enables Gannet BioChem to deliver complete GMP production services, which support various clinical and commercial therapeutic applications.

The organization prides itself on its highly experienced team and flexible production capabilities, ensuring a commitment to quality and reliability. As the biopharmaceutical industry continues to evolve, Gannet BioChem is well-positioned to meet the growing demand with innovative solutions that cater to their clients' needs.

About Ampersand Capital Partners

Founded in 1988, Ampersand Capital Partners is a middle-market private equity firm based in Boston, Massachusetts, and Amsterdam, Netherlands. With $3 billion in assets under management, it focuses on growth-oriented investments within the healthcare sector. Ampersand combines private equity expertise with operational experience to create value and promote long-term performance for its portfolio companies. Over the years, the firm has supported the development of numerous market-leading companies across various healthcare sectors.

For more details, visit GannetBioChem.com or follow them on LinkedIn.

Dr. Harry Rathore's addition to Gannet BioChem's Board marks a vital step in the company's journey, aligning strategic leadership with ambitious growth objectives aimed at shaping the future of healthcare.